Core Viewpoint - The animal health sector experienced a decline of 2.73% on September 2, with Shunlian Biological leading the drop [1][2]. Market Performance - The Shanghai Composite Index closed at 3858.13, down 0.45% - The Shenzhen Component Index closed at 12553.84, down 2.14% [1]. Individual Stock Performance - Notable gainers included: - Qudongli (code: 838275) with a closing price of 12.25, up 3.38% on a trading volume of 52,700 shares and a turnover of 63.41 million yuan - Yongshun Biological (code: 839729) with a closing price of 10.67, up 1.62% on a trading volume of 36,800 shares and a turnover of 38.93 million yuan - Significant decliners included: - Shunlian Biological (code: 688098) with a closing price of 11.79, down 6.43% on a trading volume of 169,400 shares and a turnover of 203 million yuan - Jinhe Biological (code: 002688) with a closing price of 7.20, down 4.38% on a trading volume of 527,700 shares and a turnover of 382 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 259 million yuan from institutional investors, while retail investors contributed a net inflow of 199 million yuan [2][3]. - Key stocks with significant capital flow include: - Qianhe Biological (code: 002688) with a net outflow of 67.31 million yuan from institutional investors - Shunlian Biological (code: 688098) with a net outflow of 26.38 million yuan from institutional investors [3].

Group 1 - Weisheng Information won four projects in August with a total amount of 85.5377 million yuan, accounting for 3.12% of the company's total revenue for 2024 [1] - Longqi Technology's shareholder plans to reduce its stake by up to 4.09%, equating to a maximum of 19.1916 million shares [1] - Guojin Modern's subsidiary received a drug registration certificate for injectable Nicardipine, used for treating unstable angina [3][4] Group 2 - SAIC Motor reported a total vehicle sales of 363,400 units in August, a year-on-year increase of 41.04%, with new energy vehicle sales reaching 129,800 units, up 49.89% [5] - Kuka Home plans to invest 1.124 billion yuan to build a self-owned base in Indonesia, aiming to enhance its international strategy [6] - Samsung Medical's subsidiary signed a contract for an intelligent meter project in Egypt worth 58.8 million USD, approximately 419 million yuan [8] Group 3 - North Vehicle Blue Valley's subsidiary reported a total production of 10,587 units in August, a year-on-year decrease of 15.13%, while sales increased by 3.47% [12] - Xianghe Industrial signed contracts worth 400 million yuan for railway fastener system components [13] - Hengrui Medicine's HRS9531 injection has received acceptance for its marketing authorization application [14] Group 4 - Hualu Hengsheng resumed normal production after completing maintenance on production facilities [16] - Shanghai Pharmaceuticals' hydrochloride verapamil injection passed the consistency evaluation for generic drugs [18] - Shanghai Construction received approval for debt financing tools with a registration period of two years [20] Group 5 - Kangli Elevator terminated the sale of its wholly-owned subsidiary due to the buyer's failure to obtain necessary approvals [21] - Times Wan Heng appointed Li Zhizhong as the new deputy general manager [22] - Hanma Technology reported a total truck sales of 1,051 units in August, a year-on-year increase of 58.05% [24] Group 6 - Wenzhou Hongfeng's subsidiary received a utility model patent certificate for a servo adjustment device [26] - Yibin Technology received a project designation from a domestic new energy vehicle company, with an estimated total sales of 243 million yuan over five years [28] - Star Ring Technology's H-share issuance application was accepted by the China Securities Regulatory Commission [30] Group 7 - Microchip Bio's vice president resigned for personal reasons [31] - Zhongxin Co. announced the resignation of a non-independent director due to personal reasons [32] - Changcheng Military Industry's vice chairman resigned due to retirement [35] Group 8 - Jiukang Bio received four invention patent certificates related to detection reagents [36] - Meino Bio's subsidiary changed its registered address [37] - Kuangda Technology announced a potential change in control due to a share transfer [38] Group 9 - China Rare Earth confirmed no undisclosed significant matters amid stock price fluctuations [72]

Market Overview - The animal health sector increased by 1.34% on September 1, with Jinhe Biology leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Stock Performance - Jinhe Biology (002688) closed at 7.53, up 6.06% with a trading volume of 875,700 shares and a turnover of 651 million yuan [1] - Other notable performers included *ST Lvkang (002868) with a 5.02% increase, and Shunlian Biology (688098) with a 1.78% increase [1] - The overall trading data for the animal health sector is summarized in the provided table [1] Capital Flow - The animal health sector saw a net inflow of 26.58 million yuan from institutional investors, while retail investors experienced a net outflow of 7.06 million yuan [2] - The detailed capital flow for individual stocks indicates varying levels of institutional and retail participation [3] Individual Stock Analysis - Jinhe Biology had a net inflow of 88.59 million yuan from institutional investors, while retail investors showed a net outflow of 37.91 million yuan [3] - Other stocks like Kexin Biology (688526) and *ST Lvkang (002868) also experienced mixed capital flows, with significant retail outflows [3]

Group 1 - The company has received an update on the progress of the innovative drug UB-221's Phase II clinical research from its associate company, Yangzhou Shizhi Source Biotechnology Co., Ltd. [1] - UB-221 is a humanized monoclonal antibody developed by the inventor of the anti-IgE therapy, Dr. Zhang Ziwen, and is designed to treat allergic reactions by neutralizing free IgE and inhibiting its synthesis [2][1]. - The ongoing Phase II clinical trial is a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of UB-221 in patients with chronic spontaneous urticaria (CSU), with a target enrollment of 144 patients, ultimately recruiting 145 [2]. Group 2 - The company is focused on building a world-class high-tech biopharmaceutical company and is actively expanding its business into the human innovative drug sector, leveraging its diverse biopharmaceutical technology platforms and talent reserves [3]. - The company is advancing the development of three innovative drugs: UB-221, UB-421, and UB-621, while also exploring new indications, supported by its technological expertise in synthetic peptides, genetic engineering, and mRNA [3].

Core Viewpoint - The company announced the completion of participant enrollment for the Phase II clinical trial of the innovative drug UB-221, indicating significant progress in its development [1] Group 1: Clinical Trial Progress - The company received a notification from its associate company, Shizhi Yuan, regarding the progress of the Phase II clinical trial for UB-221 [1] - A total of 145 participants have been enrolled in the clinical trial as of the date of the announcement [1] Group 2: Product and Commercial Rights - Shizhi Yuan holds all commercialization rights, including marketing authorization, research, production, and sales for UB-221 in mainland China [1] - UB-221 is a humanized monoclonal antibody developed as a subcutaneous injection, representing a next-generation product from the inventor of the anti-IgE treatment method, Dr. Zhang Ziwen [1] - The drug was originally developed by United Biomedical, Inc. (UBI), the company's second-largest shareholder [1]

申联生物医药（上海）股份有限公司（以下简称"公司"）近日收到参股公 司扬州世之源生物科技有限责任公司（以下简称"世之源"）关于创新药 UB-221 注射液 II 期临床研究进展的《告知函》，截至本公告披露日，该项目已完成全部 145 例受试者入组。现将相关情况公告如下： 一、UB-221 基本情况介绍 世之源拥有 UB-221 在中国大陆的上市许可和研发、生产、销售等全部商业 化权益。UB-221 是由公司第二大股东美国联合生物医学公司（United Biomedical, Inc., UBI）原研研发，该项目由 anti-IgE 治疗法发明人张子文博士开发的次世代 产品，是皮下注射剂型的人源化原研单抗。 UB-221 不仅可同时中和引发过敏反应的游离 IgE，亦能透过结合至 B 细胞 表面的 CD23 受体结合的 IgE 而抑制 IgE 的合成。临床前资料充分证明 UB-221 具有比同类已上市的产品更加优越的药理学特征：UB-221 不仅可中和游离 IgE， 抑制 IgE 生成；UB-221 中和游离 IgE 的效果更好；UB-221 阻断 IgE 生成的效果 更优；在食蟹猴和人类 IgE(ε,κ）基因转 ...

Group 1 - The company received a notification regarding the progress of the Phase II clinical trial for the innovative drug UB-221, which has completed the enrollment of all 145 participants [1] - The clinical trial is a Phase II, multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of UB-221 in patients with chronic spontaneous urticaria (CSU) [1] - The trial planned to recruit 144 patients but ultimately enrolled 145, with participants randomly assigned to one of five treatment groups [1] Group 2 - The company is focused on building a world-class high-tech biopharmaceutical company, leveraging its diverse biopharmaceutical technology platform and talent pool to expand its business boundaries [2] - The company is actively developing three innovative drugs: UB-221, UB-421, and UB-621, while also exploring new indications for these drugs [2] - The company aims to transition from animal health to human pharmaceuticals by utilizing its technological expertise in synthetic peptides, genetic engineering, and mRNA, alongside its capabilities in innovative drug development management [2]

Core Viewpoint - The announcement from Shenglian Bio indicates significant progress in the clinical trial of the innovative drug UB-221, which is aimed at treating chronic spontaneous urticaria (CSU) [1] Group 1: Clinical Trial Details - The clinical trial for UB-221 is a Phase II, multi-center, randomized, double-blind, placebo-controlled, parallel-group study [1] - A total of 145 subjects have been enrolled, surpassing the initial target of 144 patients [1] - Patients are randomly assigned to one of five treatment groups, receiving either 4mg/kg UB-221, 2mg/kg UB-221, 1mg/kg UB-221, 300mg Xolair, or a placebo [1] Group 2: Study Objectives - The primary endpoint of the trial is the percentage of patients achieving HSS7=0 at week 12 [1] - UB-221 is developed as a next-generation product by Dr. Zhang Ziwen, the inventor of the anti-IgE treatment method [1] Group 3: Company Background - UB-221 is a humanized original monoclonal antibody in a subcutaneous injection form, developed by the second-largest shareholder, United Biomedical, Inc. [1]

Summary of Key Points Core Viewpoint - Shenlian Bio (688098.SH) reported a decline in revenue for the first half of 2025, indicating challenges in its financial performance [1] Financial Performance - The company achieved total operating revenue of 122 million yuan in the first half of 2025, representing a year-on-year decrease of 3.68% [1] - The net profit attributable to shareholders of the parent company was -12.87 million yuan, which is an improvement of 21.64 million yuan compared to the same period last year [1] - The basic earnings per share stood at -0.03 yuan [1]

Group 1 - The board of directors of Shenyuan Biopharmaceutical (Shanghai) Co., Ltd. held its fourth meeting on August 29, 2025, with all nine directors present, ensuring the legality and validity of the resolutions made [1][2] - The board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status and operational results for the first half of 2025, with no false records or misleading statements [1][2] - The board also approved the special report on the use of raised funds from January to June 2025, stating that the use of funds complies with relevant regulations and that all projects funded by the initial public offering have been completed [2][3] Group 2 - The board agreed to disclose the semi-annual evaluation report of the "Quality Improvement and Efficiency Enhancement Action Plan" for 2025, with unanimous approval from all directors [3] - The board proposed to cancel the supervisory board and amend the company's articles of association, which is aimed at improving the corporate governance structure and aligning with the latest legal requirements [4][5] - The board decided to convene the second extraordinary general meeting of shareholders for 2025 on September 25, 2024, to discuss the cancellation of the supervisory board and other operational regulations [5][6]